NCT04757259No Longer Available不适用
An Expanded Access Protocol for Patients Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This expanded access program will provide continued access to cerdulatinib to eligible participants who experienced clinical benefit from cerdulatinib in Study 13-601 (NCT01994382) and who otherwise meet the eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has completed Portola Study 13-601 and wishes to continue treatment with cerdulatinib.
- •In the opinion of the Investigator, the potential benefit to the participant of continuing to receive cerdulatinib outweighs the risks.
- •Female participants of childbearing potential and male participants must agree to continue to abstain from sexual intercourse or to remain on an effective method of contraception during treatment and for 90 days following the last dose of protocol therapy (examples of effective methods of contraception include oral contraceptives or double barrier methods, such as condom plus spermicide or condom plus diaphragm).
- •Participant must be willing to give written informed consent and be able to adhere to dose and visit schedules.
排除标准
- •Participant requires chronic treatment with a strong CYP3A4 inhibitor or inducer.
- •Participant has a known hypersensitivity to any of the components of cerdulatinib.
- •Participant is female and is breast-feeding, pregnant, or intends to become pregnant.
- •Participant is participating in any therapeutic clinical study.
研究者
相似试验
Available
不适用
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009Breast Neoplasm Malignant FemaleNCT05134922Celcuity Inc
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataIdiopathic Arthritis (Including sJIA, pJIA, or JPsA)NCT04159597AbbVie
Available
不适用
Expanded Access for RepotrectinibNCT05926232Bristol-Myers Squibb
Available
不适用
Individual Patient Compassionate Use of FedratinibMyelofibrosisNCT03723148Celgene
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.